Morpholine, 2-(3,4-dichlorophenyl)-2-(2-((2S)-2-oxidospiro(benzo(C)thiophene-1(3H),4'-piperidin)-1'-yl)ethyl)-4-(3,4,5-trimethoxybenzoyl)-, monohydrochloride, (2R)- | 216776-73-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: Morpholine, 2-(3,4-dichlorophenyl)-2-(2-((2S)-2-oxidospiro(benzo(C)thiophene-1(3H),4'-piperidin)-1'-yl)ethyl)-4-(3,4,5-trimethoxybenzoyl)-, monohydrochloride, (2R)-
• 英文别名: [(2R)-2-(3,4-dichlorophenyl)-2-[2-(2-oxospiro[1H-2-benzothiophene-3,4'-piperidine]-1'-yl)ethyl]morpholin-4-yl]-(3,4,5-trimethoxyphenyl)methanone;hydrochloride
• CAS: 216776-73-7
• 化学式: C34H39Cl3N2O6S
• 分子量: 710.1
• InChiKey: IHDDYKNRVLPVEV-XSBGGQKVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.45
• 重原子数：
  46
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  96.8
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
  申请人：Laboratorios Almirall, S.A.

  公开号：EP2108641A1

  公开（公告）日：2009-10-14

  This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

  这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂；其制备方法；包含它们的药物组合物；以及它们在治疗中的应用。
• New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
  申请人：Almirall, S.A.

  公开号：EP2322176A1

  公开（公告）日：2011-05-18

  This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), to pharmaceutical compositions comprising them, and to their use in therapy.

  这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂，以及包含它们的药物组合物，以及它们在治疗中的应用。
• New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
  申请人：Laboratorios Almirall, S.A.

  公开号：EP2113503A1

  公开（公告）日：2009-11-04

  This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

  这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂；其制备方法；包含它们的药物组合物；以及它们在治疗中的应用。
• New 7-Phenyl-[1,2,4]triazolo[4,3-a]Pyridin-3(2H)-One Derivatives
  申请人：Bosch José Aiguade

  公开号：US20120225904A1

  公开（公告）日：2012-09-06

  This disclosure is directed to, inter alis, new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), to processes for their preparation, to pharmaceutical compositions comprising them, and to their use in therapy.

  本公开涉及到的是p38丝裂原活化蛋白激酶的新抑制剂，具有一般式(I)，关于它们的制备方法，包含它们的制药组合物以及它们在治疗中的使用。
• Combinations comprising antimuscarinic agents and PDE4 inhibitors
  申请人：Laboratorios Almirall, S.A.

  公开号：EP1891974A1

  公开（公告）日：2008-02-27

  A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.

  一种复方制剂，包括(a)PDE4 抑制剂和(b)M3 肌肽受体拮抗剂，即(3R)-1-苯乙基-3-(9H-氧杂蒽-9-甲酰氧基)-1-氮杂双环[2.2.2]辛烷，其形式为具有阴离子 X 的盐，阴离子 X 是单价或多价酸的药学上可接受的阴离子。